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The anti-inflammatory properties of macrolides have been applied to the treatment of 
inflammatory airway diseases. Although the anti-inflammatory properties of 
fluoroquinolones have been reported, no reports are available regarding a newly 
developed fluoroquinolone, garenoxacin (GRNX). To examine the immunomodulatory 
effect of GRNX, we examined the transcription and secretion of inflammatory 
cytokines by human airway epithelial cells and monocytes stimulated with 
lipopolysaccharide (LPS). A human lung epithelial cell line (A549) and a human 
monocyte cell line (THP-1) were stimulated with LPS and exposed to different 
concentrations of GRNX. The transcription and secretion of interleukin 8 (IL-8) in both 
A549 and THP-1 cells was measured by real-time PCR and an enzyme-linked 
immunosorbent assay, respectively. Treatment with GRNX significantly inhibited the 
transcription and secretion of IL-8 induced by LPS-stimulated cells through inhibitory 
ERK1/2 phosphorylation. GRNX has anti-inflammatory activity through its capacity to 
alter the secretion of IL-8 from A549 and THP-1 cell lines. Our findings suggest that 
GRNX is suitable for the treatment of LPS-induced respiratory infection and 
inflammatory airway diseases. 
 
KEYWORDS: fluoroquinolones, macrolides, immunomodulatory effect, inflammatory 
cytokine, MAPK phosphorylation 
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1. Introduction 
Diffuse panbronchiolitis is a clinicopathological disease entity that is characterized 
by chronic inflammation localized in the respiratory bronchioles (Homma et al., 1983). 
Since the effectiveness of low-dose, long-term erythromycin treatment was established, 
diffuse panbronchiolitis has become easy to control and is now curable (Kadota et al., 
1993). After the discovery of this treatment, a number of macrolides have been found to 
have significant immunomodulatory properties beyond their antibacterial activities. 
Inflammatory reactions, phagocytosis, natural cytotoxicity, cytokine production, 
antibody responses and cellular immunity are defensive mechanisms that might be 
modulated by therapeutic doses of other antimicrobial agents as well as macrolides 
(Labro, 2000; Williams, 2001). 
Fluoroquinolones are synthetic, broad-spectrum antimicrobial agents that are 
commonly used to treat a variety of infections, including systemic infections in 
immune-compromised patients (Hooper and Wolfson, 1991). In addition to their 
antimicrobial properties, certain quinolones have significant immunomodulatory 
activities in vitro and in vivo (Dalhoff, 2005). A newly developed fluoroquinolone, 
garenoxacin mesilate hydrate (GRNX), has a low mutant prevention concentration (the 
concentration that prohibits the growth of mutants from a susceptible population of 
more than 1010 cells) and a narrow mutant selection window (defined as the range 
between the minimum inhibitory concentration and the mutant prevention concentration, 
provides a means for defining the ability of an antibiotic to prevent the emergence of 
mutants) and is useful for minimizing the selection of quinolone-resistant mutants of 
pneumococcal strains (Yamamoto et al., 2009). However, the immunomodulatory 
properties of GRNX in human lung cells have not previously been examined. 
To confirm that GRNX has anti-inflammatory properties, we examined the 
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transcription and production of IL-8 in A549 and THP-1 cells. In addition, we also 
examined the phosphorylation of ERK1/2 to clarify the immunomodulatory mechanism. 
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2. Materials and Methods 
2.1 Reagents 
Clarithromycin (CAM) and GRNX were provided by Taisho-Toyama 
Pharmaceutical Co., Ltd., (Tokyo, Japan). Telithromycin (TEL) was provided by 
Sanofi-Aventis (Paris, France). Aminobenzyl penicillin (ABPC) was provided by Meiji 
Seika Pharma, Ltd., (Tokyo, Japan). Lipopolysaccharide (LPS; Pseudomonas 
aeruginosa serotype 10) was purchased from Sigma-Aldrich (St. Louis, MO, USA). 
 
2.2 Cell culture 
The human alveolar epithelial cell line A549 was purchased from the American 
Type Culture Collection (ATCC; Manassas, VA, USA) and grown as monolayers in 
tissue culture flasks (BD Falcon™; Franklin Lakes, NJ, USA) at 37C in a 5% 
CO2-humidified atmosphere. The cells were maintained in Dulbecco’s modified 
minimal essential medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS; Invitrogen). The cells were 
passaged weekly after exposure to 0.25% (w/v) trypsin. Subconfluent A549 monolayers 
(5.0  105 cells) were grown in 60-mm dishes in DMEM without FBS for 24 h before 
starting experiments. As a negative control, the A549 cells were incubated with DMEM 
alone (without FBS). The human monocytic cell line THP-1 (ATCC TIB 202) was 
purchased from ATCC and maintained in RPMI 1640 medium (Invitrogen) 
supplemented with 10% heat-inactivated FBS and 10 mM 6-melcaptoethanol (Wako 
Pure Chemical Industries, Ltd., Osaka, Japan) at 37C in a 5% CO2-humidified 
atmosphere. Assays with THP-1 cells were performed at a density of 106 cells/ml in 
6-well plates (Corning Incorporated, Corning, NY, USA). In the subsequent IL-8 
production studies, THP-1 cells were stimulated with LPS while cultured in RPMI 1640 
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with 2% heat-inactivated FBS. 
 
2.3 Real-Time PCR 
The IL-8 mRNA expression was measured by real-time PCR according to a 
procedure described previously (Amenomori et al., 2010; Hara et al., 2008). To 
determine the appropriate concentration of LPS, subconfluent A549 cells grown in 
60-mm cell culture dishes (5.0  105/dish) and THP-1 cells (106 cells/ml) in 6-well 
plates were incubated for 3 h with medium alone (control) or 0.1, 1, 10, or 100 ng/ml of 
LPS. After the appropriate concentration of LPS was determined from the preliminary 
experiments, cells were incubated for 3 h with medium alone (control) or LPS (1 ng/ml) 
in the absence or presence of antibiotics (1.0 to 10 µg/ml of CAM, TEL, GRNX, or 
ABPC). Total RNA was isolated from cultured A549 cells and THP-1 cells using an 
RNeasy Plus Mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
recommendations. A volume of pooled RNA (2 l) was reverse-transcribed in a total 
reaction volume of 21 l containing 0.5 g random hexamer primer, 20 units RNasin 
ribonuclease inhibitor, and SuperScript III First-Strand Synthesis System (Invitrogen), 
according to the supplier’s instructions. The resulting cDNA was subjected to 
quantitative real-time polymerase chain reaction (QRT-PCR). The QRT-PCR 
amplification was performed with TaqMan Gene Expression Assays for the IL-8 gene 
and human beta-actin as an endogenous control (Applied Biosystems, Foster City, CA, 
USA) in combination with the TaqMan Universal PCR Master Mix (Applied 
Biosystems). Cycle-to-cycle fluorescence emission readings were monitored and 
analyzed by the ABI PRISM 7700 Sequence Detection System (Applied Biosystems). 




2.4 Enzyme-linked immunosorbent assay (ELISA) 
The IL-8 protein production was measured by ELISA according to a procedure 
described previously (Amenomori et al., 2010; Hara et al., 2008). To determine the 
appropriate concentration of LPS, subconfluent A549 cells in 60-mm cell culture dishes 
(5.0  105/dish) and THP-1 cells in 6-well plates (106 cells/ml) were incubated for 24 h 
(A549 cells) or 9 h (THP-1 cells) with medium alone (control) or 1, 10, or 100 ng/ml of 
LPS. After the appropriate concentrations of LPS were determined from the preliminary 
experiments, cells were incubated for 24 h (A549 cells) or 9 h (THP-1 cells) with 
medium alone (control) or LPS (10 ng/ml for A549 cells or 1 ng/ml for THP-1 cells) in 
the absence or presence of antibiotics (1.0 to 10 g/ml of CAM, TEL, GRNX, or 
ABPC). Cell-free supernatants were recovered by centrifugation and stored at −80C 
until they were assayed. IL-8 levels were measured using a Quantikine human 
CXCL8/IL-8 ELISA kit according to the supplier’s instructions (R&D Systems Inc., 
Minneapolis, MN, USA). 
 
2.5 Western blotting 
ERK1/2 phosphorylation was measured by Western blotting according to a 
procedure described previously (Ishimoto et al., 2009). To determine the appropriate 
concentration of LPS for this assay, A549 cells and THP-1 cells were preincubated in 
serum-free medium at 37C for 3 h prior to the addition of 10 ng/ml, 100 ng/ml, 1 
µg/ml, or 10 µg/ml of LPS (for A549 cells) or 1, 10, or 100 ng/ml of LPS (for THP-1 
cells). Cells were incubated with LPS for 5 min. To determine the appropriate 
incubation time, cells were preincubated in serum-free medium for 3 h prior to the 
addition of 10 µg/ml of LPS for A549 cells or 100 ng/ml of LPS for THP-1 cells. Cells 
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were incubated with LPS for 5, 15, 30 or 60 min. After the LPS concentration and 
exposure time were determined from the preliminary assays, A549 cells and THP-1 
cells were preincubated in serum-free medium at 37C for 3 h in the absence or 
presence of 10 µg/ml of CAM or GRNX prior to the addition of 10 µg/ml LPS for A549 
cells or 100 ng/ml of LPS for TPH-1 cells. For Western blotting analysis of ERK1/2, 
cells were incubated with LPS for 15 min (for A549 cells) or 5 min (for THP-1 cells). 
Then, the cells were washed twice with cold PBS and suspended in 600 µl (for A549 
cells) or 40 µl (for THP-1 cells) of cell lysis buffer (Cell Signaling Technology, Inc., 
Danvers, MA, USA) that contained a 1:25 dilution of protease inhibitor cocktail 
(Nacalai Tesque Inc., Kyoto, Japan). After being kept on ice for 15 min, the lysates were 
subjected to centrifugation (20,000  g) at 4C for 15 min to obtain a cytosolic fraction. 
The protein concentration was determined by a Bradford assay (Bio-Rad, Munich, 
Germany) before storage at −70C. An aliquot of the cytosol fraction containing 20 µg 
of protein was resolved by 10% SDS-PAGE. After electrophoresis and electrophoretic 
transfer of proteins to Immun-Blot PVDF membranes (Bio-Rad), the membranes were 
blocked with 5% non-fat milk in Tris-buffered saline (pH 7.4) containing 0.1% Tween 
(TBST) for 1 h. Membranes were incubated at room temperature with a 1:1000 dilution 
of rabbit anti-human ERK 1/2 or phosphorylated ERK 1/2 antibodies (Cell Signaling 
Technology Inc.) overnight at 4C. Subsequently, the membranes were incubated with a 
secondary antibody, horseradish peroxidase-linked anti-rabbit IgG (GE Healthcare UK 
Ltd., Buckinghamshire, UK), for 1 h at room temperature. The blots were washed three 
times in TBST and incubated in enhanced chemiluminescence reagent (Amersham ECL 
Plus Western Blot detecting system; GE Healthcare). The specific bands were 
photographed by FluorChem (Cell Biosciences, Inc., Santa Clara, CA, USA). Relative 
density values of ERK1/2 were determined by densitometric analysis (NIH Image J 
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software, version 1.14o, NIH, Bethesda, MD, USA). 
 
2.6 Statistical analysis 
Values are expressed as mean ± standard error of mean (S.E.M.) for continuous 
parameters. All statistical analyses were performed with StatMate III for Macintosh 
(version 3.14, ATMS Co., Ltd., Tokyo, Japan). Results were analyzed by the Student’s 
t-test for comparison between two groups and by the non-parametric equivalents of 
analysis of variance (ANOVA) with Newman-Keuls’s multiple comparison test using 





3.1 Effect of CAM, TEL, GRNX, and ABPC on IL-8 mRNA expression in A549 and 
THP-1 cells stimulated with LPS 
To determine the effect of LPS concentration on IL-8 mRNA expression, both cell 
lines were incubated with various concentrations of LPS for 3 h. The optimal 
stimulation time was confirmed according to a procedure described previously 
(Amenomori et al., 2010; Hara et al., 2008). There was a dose-dependent increase in 
IL-8 mRNA expression by LPS stimulation (0.1 to 100 ng/ml), with significant 
increases in expression occurring at LPS concentrations greater than 1 ng/ml (Fig. 1A, 
1B). Therefore, further experiments for examining the mRNA expression were 
performed with 1 ng/ml of LPS.  
To determine if GRNX can inhibit IL-8 mRNA expression induced by LPS in 
A549 cells and THP-1 cells, A549 cells were incubated with medium alone (control) or 
1 ng/ml of LPS in the absence or presence of various antibiotics (CAM, TEL, GRNX, 
and ABPC). IL-8 mRNA expression increased in LPS-activated A549 cells (1.4 fold; 
Fig. 1C) and THP-1 cells (19 fold; Fig. 1D) at 3 h after stimulation. The addition of 
CAM, TEL, and GRNX at concentrations of 1 or 10 µg/ml significantly inhibited the 
mRNA expression of IL-8. ABPC, however, did not inhibit mRNA expression. The 1 
µg/ml concentration of all drugs (except ABPC) provided equivalent inhibition as the 10 
µg/ml concentration (no significance difference between the two concentrations). There 
was no significant difference in the level of inhibition mediated by CAM, TEL, and 
GRNX. 
 
3.2 Effect of CAM, TEL, GRNX, and ABPC on IL-8 protein production by A549 and 
THP-1 cells stimulated with LPS 
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To determine the effect of LPS concentration on IL-8 protein production, cells 
were incubated with various concentrations of LPS for 24 h (for A549 cells) and for 9 h 
(for THP-1 cells). Stimulation time for A549 cells was confirmed according to a 
procedure described previously (Amenomori et al., 2010; Hara et al., 2008). We found 
that LPS (concentrations ranging from 1 to 100 ng/ml) activated production of IL-8 in 
A549 cells in a dose-dependent manner. In A549 cells, LPS at concentrations greater 
than 10 ng/ml caused a statistically significant increase in IL-8 protein production at 24 
h (Fig. 2A). An LPS concentration of 10 ng/ml was used for further ELISA experiments 
with A549 cells. In THP-1 cells, LPS concentrations ranging from 0.1 to 100 ng/ml and 
stimulation times ranging from 6 to 24 h exhibited a stimulatory effect in which IL-8 
production was increased in a dose- and time-dependent manner (Fig. 2B). 
Concentrations of LPS greater than 1 ng/ml with stimulation times greater than 9 h 
caused statistically significant increases in IL-8 protein production (time-dependent 
experiments are not shown). Therefore, 1 ng/ml of LPS with a 9-h stimulatory time was 
used for further ELISA experiments with THP-1 cells. 
In Fig. 2C, IL-8 protein production increased in LPS-activated A549 cells by 7.2 
fold. The addition of CAM, TEL, and GRNX at concentrations of 1 or 10 µg/ml 
significantly inhibited the IL-8 protein production. ABPC did not inhibit IL-8 
production. The 1 µg/ml and 10 µg/ml concentrations of all drugs (except ABPC) 
yielded equivalent levels of inhibition. No statistically significant differences were seen 
between the two concentrations or among the three drugs (CAM, TEL, and GRNX). 
In Fig. 2D, IL-8 protein production increased in LPS-activated THP-1 cells by 
21.2 fold. By the multiple comparison test, only GRNX at 10 µg/ml significantly 
inhibited the production of IL-8. CAM, TEL and ABPC did not inhibit IL-8 production. 
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3.3 Effect of CAM and GRNX on ERK1/2 phosphorylation in LPS-stimulated A549 and 
THP-1 cells 
To determine the effect of LPS concentration and stimulation time on ERK1/2 
phosphorylation, cells were incubated with various concentrations of LPS for various 
amounts of time, as described previously (Ishimoto et al., 2009). For concentration 
determination, cells were stimulated by various concentration of LPS (10 ng/ml, 100 
ng/ml, 1 µg/ml, and 10 µg/ml for A549 cells; 1, 10, and 100 ng/ml for THP-1 cells) for 
5 min after 3 h preincubation with serum-free medium. LPS induced ERK1/2 activity in 
a dose-dependent manner (Fig. 3A and 3B). An LPS concentration of 10 µg/ml for A549 
cells and 100 ng/ml for THP-1 cells was used for further ERK1/2 activity experiments. 
For time determination, cells were stimulated by LPS for 5-60 min. LPS induced a 
transient increase in ERK 1/2 activity, which peaked at 15 min in A549 cells (Fig. 3C) 
or 5 min in THP-1 cells (Fig. 3D) and decreased at 60 min. A stimulation time of 15 min 
for A549 cells or 5 min for THP-1 cells was used for further Western blotting 
experiments. Our preliminary experiments indicated that both cell lines required a much 
higher LPS concentration to evaluate the phosphorylation of ERK1/2 with Western 
blotting than to evaluate IL-8 mRNA expression and protein production. 
The results of LPS-induced ERK1/2 activation and the effects of CAM and 
GRNX on the activation are presented in Fig. 3E and 3F. The data in Fig. 3E show that 
the addition of CAM or GRNX at a concentration of 10 µg/ml inhibited LPS-induced 
ERK 1/2 phosphorylation in A549 cells by 31.8% (± 9.5%) (P < 0.05) or 40.4% (± 
13.7%) (P < 0.05), respectively. As shown in Fig. 3F, the addition of CAM or GRNX at 
a concentration of 10 ng/ml inhibited LPS-induced ERK 1/2 phosphorylation in THP-1 




We demonstrated for the first time that GRNX significantly attenuated LPS-induced 
IL-8 transcription and production through the negative regulation of the ERK1/2 
pathway both in the human airway epithelial cell line A549 and the monocyte cell line 
THP-1. 
The major finding of the present study is that GRNX significantly inhibited 
LPS-induced IL-8 expression both in airway epithelial cells and monocytes. LPS is a 
major component of the outer membrane of Gram-negative bacteria including P. 
aeruginosa, which is a major pathogen in chronic respiratory tract infection. LPS 
induces airway epithelial cells to produce IL-8, a potent chemokine that is important in 
airway neutrophilic inflammation(Baggiolini et al., 1989). Although IL-8 plays a key 
role in the host defense mechanism through its effect on neutrophil activation, a 
continued presence of IL-8 in airway lining fluid and circulation in response to an 
inflammatory condition may lead to a variable degree of tissue damage, including 
diffuse panbronchiolitis, acute respiratory distress syndrome, and sepsis (Bellomo, 
1992; Mukae et al., 1995; Standiford et al., 1990) in which the levels of IL-8 were 
decreased by successful therapy (Kadota et al., 1993; Mattoli et al., 1991). The greater 
release of pro-inflammatory cytokines in these patients may indicate that a 
dysregulation of pro- and anti-inflammatory responses contributes to the increased 
severity. In addition, the epithelial lining of the respiratory airways is the first tissue to 
encounter pathogens and their products; therefore, it is a critical tissue in the innate 
immune system and the front line of the host defense against invading microorganisms 
(Zhang et al., 2000). Monocytes also have a pivotal role in the early cytokine response 
to a number of pathogens and/or their products, which serve as major mediators of the 
acute inflammatory response (Baumann and Gauldie, 1994). Therefore, our results that 
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GRNX inhibited IL-8 production both in LPS-stimulated A549 and THP-1 cells should 
have some value in the treatment of respiratory infection. 
A number of studies have demonstrated the immunomodulatory properties of 
macrolides (Khan et al., 1999; Morikawa et al., 2002). In addition, anti-inflammatory 
effects of quinolones, such as moxifloxacin (Araujo et al., 2002), gatifloxacin 
(Takeyama et al., 2007), ciprofloxacin (Kaji et al., 2008), and besifloxacin (Zhang and 
Ward, 2008), have also been reported. In Table 1, we list several reports about inhibitory 
effects of antibiotic on IL-8 production induced by stimuli in vitro. A few reports have 
compared the anti-inflammatory effects of fluoroquinolones and macrolides. Brau et al. 
reported that moxifloxacin but not ciprofloxacin selectively inhibited inflammatory 
cytokines in a cystic fibrosis epithelial cell line (Blau et al., 2007). In the present study, 
we demonstrated for the first time that GRNX at a concentration of 1 or 10 µg/ml, 
which reflects the peak blood levels of GRNX in vivo, inhibited IL-8 mRNA expression 
and production in A549 cells as well as CAM and TEL. In addition, our study 
demonstrated that GRNX, CAM and TEL inhibited IL-8 mRNA expression in THP-1 
cells, whereas only GRNX, but not CAM or TEL, inhibited IL-8 production. While the 
inhibition of IL-8 production by CAM and TEL in monocytes has been previously 
reported (Kikuchi et al., 2002; Leiva et al., 2008; Lotter et al., 2006), our results show 
that the effects on IL-8 production might be associated with the cell type or the 
treatment time. As shown in Table 1, the cell type, stimulus, and simulation time varied 
in similar reports. 
We demonstrated that GRNX inhibited LPS-activated phosphorylation of ERK 1/2. 
Among a variety of signal transduction molecules, MAPK is one of the signaling 
molecules required for LPS-induced IL 8 production in A549 and THP-1 cells 
(Hoffmann et al., 2002; Liu et al., 2000; Scherle et al., 1998). MAPK can act 
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independently on both the NF-kB and AP-1 transcription pathways of IL-8 production 
(Henry et al., 1998; Ishikawa et al., 1995; Standiford et al., 1990). This study indicates 
that inhibition of ERK1/2 phosphorylation could be one of the anti-inflammatory 
mechanisms of GRNX. This study has limitations in that we did not clarify whether 
GRNX affects other cell signalling pathways, as reported for other macrolides and 
fluoroquinolone, which down-regulate the expression of TLR-4 (Kaji et al., 2008), 
NF-kB or AP-1(Blau et al., 2007; Takeyama et al., 2007; Weiss et al., 2004). Further 
research is required. 
Long-term macrolide therapy (LTMT) is effective in patients with chronic bronchial 
infections such as diffuse panbronchiolitis, cystic fibrosis and bronchiectasis. After 
LTMT became widely recognized, macrolides have been reported to have not only an 
antibacterial activity but also an immunomodulatory activity (as mentioned above). 
However, sometimes acute exacerbations occur during LTMT due to bacterial 
infections including Streptococcus pneumoniae. Most of the S. pneumoniae strains 
isolated from patients receiving LTMT are resistant to macrolides while remaining 
susceptible to quinolones (Kasahara et al., 2005; Maeda et al., 2001). Given such a 
background, our results, in which the novel quinolone GRNX with greater antibacterial 
activity for penicillin-resistant S. pneumoniae attenuates LPS-induced IL-8 transcription 
and production as well as macrolides, suggest that GRNX could have clinical value in 
the management of acute exacerbations of chronic respiratory tract infections to prevent 
the spread of infection and prolonged inflammation. 
In conclusion, we have demonstrated that GRNX inhibits the LPS-stimulated 
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Fig. 1. Effects of clarithromycin (CAM), telithromycin (TEL), garenoxacin 
(GRNX) and ampicillin (ABPC) on the transcription of IL-8 mRNA 
A and B: Concentration-dependent studies. A549 (A) and THP-1 cells (B) were 
incubated with the indicated concentration of LPS for 3 h. C and D: A549 (C) and 
THP-1 cells (D) were incubated in medium alone (control) or LPS (1 ng/ml) in the 
presence or absence of CAM, TEL, GRNX and ABPC (1 or 10 µg/ml). Every 
experiment was performed in duplicate, and the values represent means ± S.E.M. of 
four independent experiments. # denotes a statistically significant difference as 
compared with control (P < 0.05), and * denotes a statistically significant difference as 
compared with LPS stimulation alone (P < 0.05).
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Fig. 2. Effects of clarithromycin (CAM), telithromycin (TEL), garenoxacin 
(GRNX) and ampicillin (ABPC) on the production of IL-8 protein 
A and B: Concentration-dependent studies. Cells were incubated with the indicated 
concentration of LPS for 24 h (A549 cells; (A)) and for 9 h (THP-1 cells; (B)). C and 
D: Cells were incubated in medium alone (control) or LPS (10 ng/ml for A549 cells (C) 
or 1 ng/ml for THP-1 cells (D)) in the presence or absence of CAM, TEL, GRNX and 
ABPC (1 or 10 µg/ml). The concentrations of IL-8 in the culture supernatants were 
measured by ELISA. Every experiment was performed in duplicate, and the values 
represent means ± S.E.M. of four independent experiments. # denotes a statistically 
significant difference as compared with control (P < 0.05), and * denotes a statistically 
significant difference as compared with LPS stimulation alone. (P < 0.05)
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Fig. 3. Effect of clarithromycin (CAM) and garenoxacin (GRNX) on the 
phosphorylated ERK (p-ERK)1/2 A and B: Concentration-dependent studies. A549 
(A) and THP-1 cells (B) were stimulated with the indicated concentration of LPS for 5 
min. C and D: Time-dependent studies. Cells were stimulated with 10 µg/ml of LPS 
(A549; (C)) or 100 ng/ml of LPS (THP-1; (D)) for the indicated amounts of time. E and 
F: Cells were preincubated with 10 µg/ml of CAM or GRNX for 3 h and then 
stimulated with 10 µg/ml of LPS for 15 min (A549; (E)) or 100 ng/ml of LPS for 5 min 
(THP-1; (F)) before performing western blot analysis. The ratio of p-ERK to total-ERK 
was calculated for each sample. Every experiment was performed in duplicate, and the 
values are the means ± S.E.M. of four independent experiments. # denotes a statistically 
28 
significant difference as compared with control (P < 0.05), and * denotes a statistically 
significant difference compared with the results for the LPS-stimulated cells without 
antibiotic (P < 0.05). 
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Table 1. Inhibitory effects of antibiotic on IL-8 production induced by stimuli in 
vitro. Inhibitory ratios of control stimulator exposure are quoted from the text of 
references or measured from the graphs provided in each reference. In the case that 
several cytokines were measured, results of only IL-8 measurement are shown in this 
table. Underlined numbers denote a statistically significant concentration. 
Abbreviations: hPBMC, human peripheral blood mononuclear cell; NHBE, normal 
human bronchial epithelial cell; EM, erythromycin; CAM, clarithromycin; AZM, 
azithromycin; TEL, telithromycin; JM, josamycin; CEZ, cefazolin; GRNX, 
garenoxacin; MFLX, moxifloxacin; CPFX, ciprofloxacin; GFLX, gatifloxacin. 
 
